Nivolumab

Department of Health written question – answered on 14th June 2016.

Alert me about debates like this

Photo of Jim Shannon Jim Shannon Shadow DUP Spokesperson (Health), Shadow DUP Spokesperson (Transport), Shadow DUP Spokesperson (Equality)

To ask the Secretary of State for Health, if he will instruct officials of his Department to continue to work with the manufacturers of Nivolumab on ensuring that patients with non-squamous non-small cell lung cancer can access that drug through the NHS.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence (NICE) is currently appraising nivolumab (Opdivo) for non-squamous non-small cell lung cancer.

As part of its appraisal, the NICE has considered a patient access scheme (PAS) proposal from the manufacturer Bristol-Myers Squibb which has been agreed by Ministers. Departmental officials are open to discussing any further proposals regarding the PAS with the company.

The NICE currently expects to publish its final guidance in September 2016.

In the absence of the NICE guidance, it is for commissioners to make funding decisions based on the available evidence.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.